{"id":3017,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2019-02-07","marketCap":709.5020141601562,"name":"Alector Inc","phone":"14152315660","outstanding":95.01000213623047,"symbol":"ALEC","website":"https://alector.com","industry":"Biotechnology"},"price":7.2675,"year":2024,"month":3,"day":2,"weekday":"Saturday","title":"Performance Analysis of Alector Inc Stock","date":"2024-03-02","url":"/posts/2024/03/02/ALEC","content":[{"section":"Introduction","text":"Alector Inc operates in the biotechnology industry and focuses on developing treatments for neurodegenerative diseases. This analysis will evaluate the performance of their stock in comparison to their competitors within the same industry."},{"section":"Stock Performance","text":"Alector Inc's stock has shown significant volatility over the past year. It started the year with a strong upward trend, reaching its peak in Q2. However, it experienced a decline in Q3 and Q4, resulting in an overall negative performance for the year. The stock's price-to-earnings (P/E) ratio has also been relatively high compared to its competitors."},{"section":"Competitors' Performance","text":"When comparing Alector Inc with its competitors in the biotechnology industry, we observed mixed results. Some competitors have shown strong growth and relatively stable stock performance throughout the year, while others have faced similar volatility to Alector Inc. It is important to note that each competitor operates in different segments of the industry, which can significantly impact their respective performances."},{"section":"Factors Influencing Performance","text":"Several factors can influence the performance of Alector Inc stock and its competitors within the biotechnology industry. These factors include clinical trial results, regulatory approvals, partnerships with larger pharmaceutical companies, and overall market sentiment towards the industry. It is crucial to analyze these factors in detail to understand the reasons for the divergent performances among the stocks."},{"section":"Investment Recommendation","text":"Based on the analysis, it is essential to carefully evaluate the potential of Alector Inc stock in comparison to its competitors. Investors should consider the company's pipeline of drug candidates, ongoing clinical trials, and partnerships. Additionally, it is important to monitor the overall market conditions and investor sentiment towards the biotechnology industry before making any investment decisions."},{"section":"Conclusion","text":"In conclusion, Alector Inc's stock performance has been volatile and negative overall. However, it is crucial to compare its performance with other competitors within the biotechnology industry, taking into account the specific factors influencing each company. Investors should thoroughly analyze the company's fundamentals and the industry landscape before making any investment decisions."},{"section":"","text":""},{"section":"","text":""}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1709293551,"headline":"The Alector, Inc. (NASDAQ:ALEC) Full-Year Results Are Out And Analysts Have Published New Forecasts","id":126258414,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"ALEC","publisher":"Yahoo","summary":"Alector, Inc. ( NASDAQ:ALEC ) defied analyst predictions to release its full-year results, which were ahead of market...","url":"https://finance.yahoo.com/news/alector-inc-nasdaq-alec-full-114551441.html"},{"category":"company","date":1709203279,"headline":"What You Need To Know About The Alector, Inc. (NASDAQ:ALEC) Analyst Downgrade Today","id":126197236,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"ALEC","publisher":"Yahoo","summary":"One thing we could say about the analysts on Alector, Inc. ( NASDAQ:ALEC ) - they aren't optimistic, having just made a...","url":"https://finance.yahoo.com/news/know-alector-inc-nasdaq-alec-104119075.html"},{"category":"company","date":1709185260,"headline":"Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)","id":126211306,"image":"","symbol":"ALEC","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3374304747"},{"category":"company","date":1709146930,"headline":"Q4 2023 Alector Inc Earnings Call","id":126189870,"image":"","symbol":"ALEC","publisher":"Yahoo","summary":"Q4 2023 Alector Inc Earnings Call","url":"https://finance.yahoo.com/news/q4-2023-alector-inc-earnings-190210532.html"},{"category":"company","date":1709133214,"headline":"Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript","id":126189871,"image":"https://s.yimg.com/ny/api/res/1.2/bDnysnr3ah5C7wXjqhCFKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/d8ccf302d7c67e9b92027f75d528e57e","symbol":"ALEC","publisher":"Yahoo","summary":"Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript February 27, 2024 Alector, Inc. beats earnings expectations. Reported EPS is $-0.49, expectations were $-0.8. Alector, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing […]","url":"https://finance.yahoo.com/news/alector-inc-nasdaq-alec-q4-151334072.html"},{"category":"company","date":1709121600,"headline":"Alector to Participate in Upcoming Healthcare Conferences","id":126189872,"image":"","symbol":"ALEC","publisher":"Yahoo","summary":"SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference (Boston, Massachusetts) Tuesday, March 5, 2024, at 10:30 a.m. ET, panel Leerink Partners Global Biopharma Conference (Miami, Florida) Tuesday, March 12, 2024, at 10:40 a.m. ET, corporate presentatio","url":"https://finance.yahoo.com/news/alector-participate-upcoming-healthcare-conferences-120000594.html"},{"category":"company","date":1709102340,"headline":"Optimistic Buy Rating for Alector’s AL002 Based on Promising Alzheimer’s Disease Trial Biomarkers and TREM2 Signaling Efficacy","id":126211308,"image":"","symbol":"ALEC","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3372167828"},{"category":"company","date":1709095080,"headline":"Alector: Cautious Hold Rating Ahead of Key Clinical Trial Milestones and Financial Assessment","id":126211309,"image":"","symbol":"ALEC","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3372045564"},{"category":"company","date":1709087880,"headline":"Alector (ALEC) Receives a Buy from Barclays","id":126211310,"image":"","symbol":"ALEC","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3371950309"},{"category":"company","date":1709076190,"headline":"Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript","id":126174360,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"ALEC","publisher":"SeekingAlpha","summary":"Alector, Inc. (NASDAQ:NASDAQ:ALEC) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ETCompany ParticipantsKatie Hogan - Investor RelationsArnon...","url":"https://seekingalpha.com/article/4674104-alector-inc-alec-q4-2023-earnings-call-transcript"},{"category":"company","date":1709070408,"headline":"Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results","id":126173691,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"ALEC","publisher":"Yahoo","summary":"Key Financial Highlights and Clinical Advancements","url":"https://finance.yahoo.com/news/alector-inc-alec-reports-fourth-214648033.html"},{"category":"company","date":1709067900,"headline":"Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update","id":126173692,"image":"https://media.zenfs.com/en/globenewswire.com/e31cf5f3689b27465496cb9220208a33","symbol":"ALEC","publisher":"Yahoo","summary":"Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023 First participant in the global PROGRESS-AD Phase 2 clinical trial of AL101 in early AD dosed in Q1 2024 Latozinemab granted FDA’s Breakthrough Therapy Designation for frontotemporal dementia due to a mutation in the progranulin gene (FTD-GRN) Achieved target enrollment in pivotal INFRONT-3 latozinemab Phase 3 tria","url":"https://finance.yahoo.com/news/alector-reports-fourth-quarter-full-210500406.html"},{"category":"company","date":1709051046,"headline":"Alector: Q4 Earnings Snapshot","id":126171759,"image":"","symbol":"ALEC","publisher":"Finnhub","summary":"SOUTH SAN FRANCISCO, Calif. — SOUTH SAN FRANCISCO, Calif. — Alector Inc. on Tuesday reported a loss of $41.4 million in its fourth quarter. On a per-share basis, the South San Francisco,...","url":"https://finnhub.io/api/news?id=9d53579da4f2c699e6915bdf15f68de2e6f9f7830e3fa1b8c661a08f91403c3c"},{"category":"company","date":1709013960,"headline":"TD Cowen Sticks to Their Buy Rating for Alector (ALEC)","id":126211314,"image":"","symbol":"ALEC","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3371188910"},{"category":"company","date":1709007240,"headline":"Alector GAAP EPS of -$0.49 beats by $0.28, revenue of $15.2M beats by $6.36M","id":126211315,"image":"","symbol":"ALEC","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3370962522"},{"category":"company","date":1709006640,"headline":"Earnings Scheduled For February 27, 2024","id":126165914,"image":"","symbol":"ALEC","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3369922314"},{"category":"company","date":1709005860,"headline":"Recap: Alector Q4 Earnings","id":126211317,"image":"","symbol":"ALEC","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3370920400"},{"category":"company","date":1709004420,"headline":"Alector reports Q4 EPS (49c), consensus (77c)","id":126211319,"image":"","symbol":"ALEC","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3370873542"},{"category":"company","date":1708942020,"headline":"Earnings Outlook For Alector","id":126152278,"image":"","symbol":"ALEC","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3368332309"},{"category":"company","date":1708922220,"headline":"Notable earnings after Tuesday's close","id":126148531,"image":"","symbol":"ALEC","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3368966019"},{"category":"company","date":1708922220,"headline":"Alector FY 2023 Earnings Preview","id":126152279,"image":"","symbol":"ALEC","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3368966029"},{"category":"company","date":1708463100,"headline":"Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call","id":126003025,"image":"https://media.zenfs.com/en/globenewswire.com/e31cf5f3689b27465496cb9220208a33","symbol":"ALEC","publisher":"Yahoo","summary":"Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PTSOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2023, and provide a full-year business update. A press release detailing fourth quarter results w","url":"https://finance.yahoo.com/news/alector-host-fourth-quarter-full-210500353.html"},{"category":"company","date":1708441252,"headline":"Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline","id":125992216,"image":"https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781","symbol":"ALEC","publisher":"Yahoo","summary":"Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","url":"https://finance.yahoo.com/news/earnings-preview-alector-alec-q4-150052351.html"}]}